April 6, 2018 / 5:46 AM / 7 months ago

BRIEF-Thrombogenics Announces Positive Preclinical Data On THR-149

April 6 (Reuters) - THROMBOGENICS NV:

* ANNOUNCES THAT POSITIVE PRECLINICAL DATA ON PLASMA KALLIKREIN (PKAL) INHIBITORS IN DIABETIC MACULAR EDEMA (DME) HAVE BEEN PUBLISHED IN JOURNAL OF MEDICINAL CHEMISTRY

* POSITIVE OUTCOMES OF PKAL INHIBITORS ON TISSUE EDEMA SUPPORTS THEIR DEVELOPMENT AS POSSIBLE TREATMENTS FOR DME AND DR VIA A VEGF-INDEPENDENT MECHANISM

* PRECLINICAL STUDY CONFIRMED THAT BICYCLIC PEPTIDES HAVE NANOMOLAR TO PICOMOLAR POTENCIES, ARE STABLE IN BIOLOGICAL MATRICES AND REPORTED PROLONGED RETENTION IN EYE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below